London, 14 - 15 March 2023

Schedule

Create your personal agenda –check the favourite icon

Mar 148:30
Conference pass

Opening remarks

Keynotes
Jessica Robinson, Project Director, Terrapinn
Keynote
Mar 149:10
Conference pass

Tackling manufacturing issues to deliver ATMPs to Patients

Keynotes

Presentation from LonzaSpeaker TBC

Keynote
Mar 149:30
Conference pass

Panel: Being realistic about the future and commercial sustainability of ATMPs

Keynotes
  • Where are we really?
  • What does the future hold?
  • How can we guarantee success?
  • How do we really bring the cost down?
  • How do we build on the success of companies like Kite?
Keynote
Mar 1410:10
Conference pass

Establishing a platform strategy for cell and gene therapy supply chains

Keynotes
Keynote
Mar 1411:30
Conference pass

Roundtables

Keynotes
Roundtable 10: Challenges for strategy and practice in the pre-clinical and early clinical stages of CGT development
Roundtable 11: How a data strategy can help tackle digitalisation challenges faced by cell and gene therapy companies
Roundtable 12: Streamlining your vector processing pipeline
Paul S Carter, Director, Head Vector Processing, Quell Therapeutics
Roundtable 13: Securing commercially valuable IP and navigating the competitor landscape
Roundtable 15: Implementation of continuous processes for cell and gene therapies
Manuel Carrondo, Professor, iBET: Instituto de Biologia Experimental e Tecnológica
Roundtable 16 From early research to the market: leveraging communication for better outcomes
Roundtable 18: Accelerating the adoption of gene therapies
Hannah Crocker, Project Lead, Life Sciences Hub Wales Ltd
Roundtable 1: Collaboration between patient groups and industry
Ron Jortner, Managing Director, Masthead Biosciences
Roundtable 20: Navigating access and reimbursement for cell and gene therapies
Roundtable 21: Academic Translation
Susie Maier, Translational Research Facilitator, University of Bristol
Roundtable 2: Interactions with regulatory Authorities for SMEs and Academia
Roundtable 3: In vivo generation of therapeutic cells – CAR-T and beyond
Roundtable 4: Tackling delivery technology and other challenges
Sarfaraz Niazi, Adjunct Professor, University of Illinois
Roundtable 5: Commercial aspects: what you need to know about running a cell therapy company in 2022 & how to stand out
Roundtable 6: CGT Supply Chain Automation From First Patient
Roundtable 7: Tackling the challenges of getting to commercial level
Imen Mestiri, Business Development Manager, genethon
Roundtable 8: Safety profiling of gene edited therapies
Jennifer Harbottle, Associate Director, AstraZeneca
Roundtable 9: Successful elements of fundraising for translation
Roundtables
Mar 1413:29
Conference pass

Chair: Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)

Track 1: Evidence, pricing and access
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Track 1: Evidence, pricing & access
Mar 1413:29
Conference pass

Chair: Stefanos Theoharis, CBO, Bone Therapeutics

Track 2: Gene modified cell therapy
Track 2: Gene modified cell therapy
Mar 1413:29
Conference pass

Chair: Miguel Forte, President Elect, ISCT; Entrepreneur in Residence, AdBio Partners

Track 3: Cell therapy
Track 3
Mar 1413:29
Conference pass

Chair: Eric Michael David, CEO, BioBridge Gene Therapy

Track 4: Gene Therapy
Track 4
Mar 1413:29
Conference pass

Chair: Patrick J. Hanley, Chief and Director, Cellular Therapy Program, Children's National Health System

Track 5: Cell therapy manufacture
Track 5
Mar 1413:29
Conference pass

Chair: Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering, UCL

Track 6: Viral vector manufacture
Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering, UNIVERSITY COLLEGE LONDON
Track 6: Viral Vector Manufacturing
Mar 1413:29
Conference pass

Chair: Lior Raviv, CTO, Pluri

Track 7: Supply chain and logistics
Lior Raviv, Vice President, Development & Operations, Pluri
Mar 1413:29
Conference pass

Chair: David Morrow, Scientific Program Manager, EATRIS

Track 8: Innovation Showcase
Mar 1413:29
Conference pass

Chair: Owen Smith, Partner, 4BIO Capital

Track 9: Start-up theatre
Owen Smith, Partner, 4BIO Capital
Mar 1413:29
Conference pass

Chair: Stefanos Theoharis, CBO, Bone Therapeutics

Track 9: Start-up theatre
Mar 1413:30
Conference pass

The last 5 years in ATMPs: What went wrong with Zynteglo and what are the lessons learned from Libmeldy?

Track 1: Evidence, pricing and access
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Track 1: Evidence, Pricing & Access
Mar 1413:30
Conference pass

CAR-Macrophages: a novel approach to immunotherapy

Track 2: Gene modified cell therapy
Mar 1413:30
Conference pass

Clinical development of iPSC-derived mesenchymal stem cells

Track 3: Cell therapy
Track 3
Mar 1413:30
Conference pass

Unlocking the full potential of in vivo gene therapy

Track 4: Gene Therapy
Track 4
Mar 1413:30
Conference pass

Cell and gene therapy standardisation

Track 5: Cell therapy manufacture
Track 5
Mar 1413:30
Conference pass

Potency assay development: lifecycle approach for cell and gene therapy products

Track 6: Viral vector manufacture
Amandine Breton, Associate Director, Orchard Therapeutics
Track 6
Mar 1413:30
Conference pass

Potency assay development: lifecycle approach for cell and gene therapy products

Track 6: Viral vector manufacture
Amandine Breton, Associate Director, Orchard Therapeutics
Mar 1413:30
Conference pass

Real life experiences of managing complexity in cell and gene therapy programmes

Track 7: Supply chain and logistics
Mark Edwards, Senior Director, Supply Chain Management, Sangamo Therapeutics
Track 7: Supply Chain and Logistics
Mar 1413:30
Conference pass

Genetic changes in human pluripotent stem cells: Implications for safety and efficacy of cell therapies

Track 8: Innovation Showcase
Mar 1413:30
Conference pass

How to attract investment into cell and gene therapy: hear how different investors decide on who and what they invest in, and why

Track 9: Start-up theatre
Sven Kili, Chief Executive Officer, Antion Biosciences
Raghuram Selvaraju, Managing Director, Senior Analyst, Healthcare, H.C. Wainwright
Owen Smith, Partner, 4BIO Capital
Mar 1413:50
Conference pass

AMNOG 2.0 – New legal framework for pricing of innovative drugs in Germany

Track 1: Evidence, pricing and access
Thomas Mueller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Track 1: Evidence, pricing and access
Mar 1413:50
Conference pass

The Power of the Collective: how collaboration will drive growth within the CGT ecosystem

Track 3: Cell therapy
Mar 1413:50
Conference pass

Rare diseases drug development: challenges and opportunities

Track 4: Gene Therapy
Track 4
Mar 1413:50
Conference pass

Standardization of Cell Therapy Manufacturing Using Closed Processes

Track 5: Cell therapy manufacture
Mar 1413:50
Conference pass

Integrated Solutions for Global Viral Vector Manufacture

Track 6: Viral vector manufacture
Michael Baker, Senior Director Viral Gene Therapy, Fujifilm
Mar 1413:50
Conference pass

Starting Material Matters in Cell Therapy – Highly Innovative Approach with Curate Cell Processing System

Track 8: Innovation Showcase
Mar 1414:10
Conference pass

Putting things into perspective: How well are GT's performing

Track 1: Evidence, pricing and access
Francis Pang, SVP Global Market Access and Geographic Expansion, Orchard Therapeutics
Track 1: Evidence, pricing & access
Mar 1414:10
Conference pass

Flexible approaches to analytical characterization of CAR T manufacturing using mass cytometry

Track 2: Gene modified cell therapy
Track 2: Gene modified cell therapy
Mar 1414:10
Conference pass

Developing optimal stem cell expansion and differentiation protocols for advanced cell therapies

Track 3: Cell therapy
Track 3
Mar 1414:10
Conference pass

Current gene delivery systems & what does the future hold?

Track 4: Gene Therapy
Track 4
Mar 1414:10
Conference pass

Particulate Strategy for Cell Gene Therapy products

Track 5: Cell therapy manufacture
Track 5
Mar 1414:10
Conference pass

Establishment of perfusion and automated process control strategies for high yield ATMP Manufacture

Track 6: Viral vector manufacture
Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering, UNIVERSITY COLLEGE LONDON
Track 6
Mar 1414:10
Conference pass

Establishment of perfusion and automated process control strategies for high yield ATMP Manufacture

Track 6: Viral vector manufacture
Qasim Rafiq, Associate Professor in Cell and Gene Therapy Bioprocess Engineering, UNIVERSITY COLLEGE LONDON
Track 6: Viral Vector Manufacture
Mar 1414:10
Conference pass

Cryopreservation of HPC (A)/PBSCs and DLI/PBMCs – what have we learnt from Covid?

Track 7: Supply chain and logistics
Track 7: Supply Chain and Logistics
Mar 1414:10
Conference pass

Cryopreservation of HPC (A)/PBSCs and DLI/PBMCs – What have we learnt from Covid?

Track 7: Supply chain and logistics
Mar 1414:10
Conference pass

New stem cell-derived exosome drug delivery system

Track 8: Innovation Showcase
Mar 1414:10
Conference pass

Cellular Re-programming utilizing the Immune system

Track 9: Start-up theatre
Michal Golan Mashiach, CEO, Edity Therapeutics
Track 9: Start-up Theatre
Mar 1414:30
Conference pass

Title TBC

Track 1: Evidence, pricing and access
Lung-I Cheng, Vice President of Cell and Gene Therapy Commercial Solutions, AmerisourceBergen
Track 1: Evidence, pricing and access
Mar 1414:30
Conference pass

Panel: New frontiers to improve post-transplant immune reconstitution

Track 2: Gene modified cell therapy
Stefan Nierkens, Principal Investigator Boelens/Nierkens Research Group & Head U-DAIR, UMC Utrecht
Track 2: Gene modified cell therapy
Mar 1414:30
Conference pass

The benefits of digital transformation within cell and gene therapy companies

Track 3: Cell therapy
Mar 1414:30
Conference pass
Mar 1414:30
Conference pass

Key Considerations in Design of a Cell and Gene Therapy Processing Facility

Track 5: Cell therapy manufacture
Mar 1414:30
Conference pass

Addressing global commercial challenges in vector supply as an academic institution

Track 6: Viral vector manufacture
Henry Pegram, Head of Business Development, Kings College London Gene Therapy Vector Facility
Track 6: Viral Vector Manufacture
Mar 1414:30
Conference pass

Addressing logistical challenges – How albumin can improve storage and stability of cells

Track 7: Supply chain and logistics
Phil Morton, Science Director of Bioprocess Characterization, Albumedix
Mar 1414:30
Conference pass

Gene editing induced gene silencing technology for advanced cell therapy development

Track 8: Innovation Showcase
Tom Payne, Chief Operating Officer, Laverock Therapeutics
Mar 1414:30
Conference pass

Complete tailor-made single-cell sequencing services

Track 9: Start-up theatre
Track 9: Start-up Theatre
Mar 1414:50
Conference pass

Biotech financing: where are we going in 2023?

Track 1: Evidence, pricing and access
Sven Kili, Chief Executive Officer, Antion Biosciences
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Mar 1414:50
Conference pass

Logistical implications of global cell-based therapies for diabetic kidney disease: early phase III lessons learned diabetic kidney disease

Track 3: Cell therapy
Track 3
Mar 1414:50
Conference pass

Non-CAR-T cancer gene therapies: where we stand, where we are going

Track 4: Gene Therapy
Massimo Dominici, Associate Professor Medical Oncology, University of Modena and Reggio Emilia
Mar 1414:50
Conference pass

Systematic NK process design approaches – which CQAs and CPPs do we need to look at

Track 5: Cell therapy manufacture
Bence Kozma, PostDoc, TU WIen
Track 5
Mar 1414:50
Conference pass

Efficient and scalable Production of AAV Gene Therapies Using a Baculovirus and Insect Cell Expression System

Track 6: Viral vector manufacture
Pranav Puri, Sr Scientist, Vectorytx Amsterdam
Track 6: Viral Vector Manufacture
Mar 1414:50
Conference pass

Cord-Blood Derived T-Regulatory Cells

Track 7: Supply chain and logistics
Track &:Supply and Chain Logistics
Mar 1414:50
Conference pass

Delivering the promise of nucleic acid therapeutics

Track 8: Innovation Showcase
Mar 1415:10
Conference pass

Don’t forget the quality of your raw materials in gene therapy products

Track 2: Gene modified cell therapy
Mar 1415:10
Conference pass

AUTO4 – a TRBC1 targeted CAR T cell therapy for T-cell lymphomas

Track 3: Cell therapy
Chris Williams, SVP, Corporate Development, Autolus Therapeutics
Mar 1415:10
Conference pass

Retinal Gene Therapy: from Gene specific to gene agnostic approaches

Track 4: Gene Therapy
Daniel Chung, Chief Medical Officer�, Sparingvision
Track 4
Mar 1415:10
Conference pass

Automation of hematopoietic stem cell transduction: Results of a head-to-head comparison between a manual and an automated procedure

Track 5: Cell therapy manufacture
Mar 1415:10
Conference pass

Viral vector process design - Striking the right balance of speed and development

Track 6: Viral vector manufacture
Mar 1415:10
Conference pass

An automated workflow for highly efficient cloning of iPSCs in cell therapy manufacturing

Track 8: Innovation Showcase
Mar 1415:10
Conference pass

Presentation by Medace

Track 9: Start-up theatre
Jessica Gerards, Quality Manager, Medace
Track 9: Start-up Theatre
Mar 1416:00
Conference pass

Panel: Finding the right framework for reimbursement and market access

Track 1: Evidence, pricing and access
Alexander Natz, Secretary General, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Manel Juan, Immunologist, Hospital Clínic de Barcelona
Thomas Mueller, Head Of Directorate General 1 - Drugs, Medical Devices, Biotechnology, Federal Ministry of Health Germany
Doug Danison, Head of Commercial, Cell and Gene Therapy Unit, Bayer Pharma AG
Track 1: Evidence, pricing & access
Mar 1416:00
Conference pass

CAR T-cell immunotherapy of solid tumours: moving through the generations

Track 3: Cell therapy
Track 3
Mar 1416:00
Conference pass

Regmed XB’s pilot factory for regenerative medicine

Track 5: Cell therapy manufacture
Erik Eijrond, COO, RegMed XB
Track 5
Mar 1416:00
Conference pass

Extended Characterization of AAV Capsids by Mass Spectrometry to Determine Critical Quality Attributes

Track 6: Viral vector manufacture
Track 6
Mar 1416:00
Conference pass

Transforming Incubator of Life into Innovative Treatments: allogeneic Amnion Epithelial Stem Cells to treat congenital and chronic disorders without immunosuppression

Track 8: Innovation Showcase
Mar 1416:20
Conference pass

Off-the-shelf clinical options – new data

Track 2: Gene modified cell therapy
Track 2: Gene modified cell therapy
Mar 1416:20
Conference pass

An autologous ATMP to treat traumatic spinal Cord injuries, from concept to clinical testing

Track 3: Cell therapy
Track 3
Mar 1416:20
Conference pass

How Innovation and Collaborations are Accelerating Gene Therapy Development

Track 4: Gene Therapy
Track 4
Mar 1416:20
Conference pass

Enhancing Cell Therapy Development Through Advanced Protein Production and Antibody Development Platforms

Track 5: Cell therapy manufacture
Mar 1416:20
Conference pass

From Rare diseases to Cancer. How can EATRIS support the ATMP developer?

Track 8: Innovation Showcase
Mar 1416:20
Conference pass

Targeting of HLA-G positive tumors with cytotoxic immune cells engineered with a Chimeric ILT-Receptor

Track 9: Start-up theatre
Track 9: Start-up Theatre
Mar 1416:40
Conference pass

Extracorporeal gene delivery for the in vivo engineering of therapeutic cells

Track 2: Gene modified cell therapy
Mar 1416:40
Conference pass

Developing high-content imaging assays for precision medicine and stem cell disease modelling

Track 3: Cell therapy
Mar 1416:40
Conference pass

Clinical trial update

Track 4: Gene Therapy
Track 4
Mar 1416:40
Conference pass

Implementation of Continuous processes for cell and gene therapy applications

Track 5: Cell therapy manufacture
Manuel Carrondo, Professor, iBET: Instituto de Biologia Experimental e Tecnológica
Mar 1416:40
Conference pass

3 years on: an in-house developed External Assurance Programme for Advanced Therapies, the first Academic Programme in Europe

Track 8: Innovation Showcase
Antonio Rodriguez, Deputy Qualified Person. Cellular Manufacturing Unit, Regional University Hospital -Biomedical Research Institute (IBIMA) Málaga
Mar 1417:00
Conference pass

miCAR Multiplex Cell Engineering: The new standard

Track 2: Gene modified cell therapy
Sven Kili, Chief Executive Officer, Antion Biosciences
Mar 1417:00
Conference pass

Pioneering macrophage cell therapy for advanced liver disease

Track 3: Cell therapy
Mar 1417:00
Conference pass

Directed Evolution of AAV Gene Delivery Systems for Clinical Gene Therapy

Track 4: Gene Therapy
Track 4
Mar 1417:00
Conference pass

Academic multi-tasking

Track 5: Cell therapy manufacture
Mar 1417:00
Conference pass

Little, useful secrets on how to create and execute an effective quantum computing strategy Fausto Artico, Global R&D Tech Head and Director of Innovation and Data Science, GSK (confirmed)

Track 8: Innovation Showcase
Mar 1417:00
Conference pass

The DNA & RNA revolution

Track 9: Start-up theatre
Track 9: Start-up Theatre
Mar 1417:20
Conference pass

Panel: New frontiers in cell therapy, moving from auto to allo to in-vivo

Track 2: Gene modified cell therapy
Track 2: Gene modified cell therapy
Mar 1417:20
Conference pass

Panel: The pros and cons of alternative allogeneic approaches

Track 3: Cell therapy
Track 3
Mar 1417:20
Conference pass

Panel: The Brain: Gene Therapy’s Next Frontier

Track 4: Gene Therapy
Track 4
Mar 1417:20
Conference pass

Panel: Innovative solutions to challenges in manufacturing

Track 5: Cell therapy manufacture
Sven Kili, Chief Executive Officer, Antion Biosciences
Sophie Mountcastle, Network Manager - Innovation Hubs for Gene Therapies, Medical Research Council
Mar 1417:20
Conference pass

Panel discussion: Addressing the skill shortage in Advanced Therapies

Track 8: Innovation Showcase
Angela Justice, Chief People Officer�, TCR² Therapeutics
Jasmin Kee, Bioprocessing Consultant, KeeBio
Manuel Carrondo, Professor, iBET: Instituto de Biologia Experimental e Tecnológica
Mar 1417:20
Conference pass

ReStart CNS Regenerating Cells

Track 8: Innovation Showcase
Chris Ahuja, Chief Executive Officer, Inteligex
Track 8: Innovation Showcase

Create your personal agenda –check the favourite icon

Mar 159:00
Conference pass

Keynote presentation: Translating innovation from academia to industry

Keynotes
Mar 159:30
Conference pass

Keynote panel: Revision of ATMP legislation

Keynotes

Feedback, sourcing, accelerated reviews

Plenary: Opening Keynotes
Mar 1510:29
Conference pass

Chair: Snehal Naik, Head of Regulatory Policy; Strategy Leader (Ocular), Spark Therapeutics

Track 1: Regulation
Track 1: Commercialisation and Business Development
Mar 1510:29
Conference pass

Chair: Peter Olagunju, CTO, TCR2

Track 2: Gene modified cell therapy
Peter Olagunju, Chief Technology Officer, TCR² Therapeutics
Track 2
Mar 1510:29
Conference pass

Chair: Francesco Dazzi, Senior Medical Director, AstraZeneca

Track 3: Cell therapy
Mar 1510:29
Conference pass

Chair: Sakis Mantalaris, Professor, Trinity College Dublin

Track 5: Cell therapy manufacture
Track 5
Mar 1510:29
Conference pass

Chair: Manuel Carrondo, Vice President, IBET

Track 6: Viral vector manufacture
Manuel Carrondo, Professor, iBET: Instituto de Biologia Experimental e Tecnológica
Mar 1510:29
Conference pass
Mar 1510:29
Conference pass

Track 8: Innovation showcase

Track 8: Innovation Showcase
Sven Kili, Chief Executive Officer, Antion Biosciences
Mar 1510:30
Conference pass

Regulatory case studies: young + old companies

Track 1: Regulation
Vicki Coutinho, Gamma Delta Regulatory Affairs and Quality, Gammadelta Therapeutics
Track 1: Regulation
Mar 1510:30
Conference pass

Choosing the right GMP partner for your CRISPR-enabled cell and gene therapy

Track 2: Gene modified cell therapy
Mar 1510:30
Conference pass

Optimising a method for producing a living nerve growth guide designated “EngNT”, which is intended as an ‘off-the-shelf’ nerve replacement

Track 3: Cell therapy
John Sinden, Chief Executive Officer, Glialign Limited
Track 3
Mar 1510:30
Conference pass

Gene therapy for the treatment of wet age related macular degeneration, a highly prevalent ocular disease

Track 4: Gene Therapy
Richard Beckman, Chief Medical Officer, Adverum Biotechnologies
Track 4
Mar 1510:30
Conference pass

Identifying cost-effective manufacturing strategies for ATMPs

Track 6: Viral vector manufacture
Track 6
Mar 1510:30
Conference pass

Bringing manufactured blood cell therapies to the clinic

Track 7: Clinical Development and Trials
Mar 1510:30
Conference pass

Staying One Step Ahead of Workforce Trends Impacting Your Business

Track 8: Innovation Showcase
Angela Justice, Chief People Officer�, TCR² Therapeutics
Mar 1510:30
Conference pass

Investor Panel

Track 9: Start-up theatre
Dominic O'Regan, Business Development Consultant & Investor, New Mosaic
Raghuram Selvaraju, Managing Director, Senior Analyst, Healthcare, H.C. Wainwright
Track 9: Start-up Theatre
Mar 1510:50
Conference pass

Panel: Tackling large scale regulatory challenges

Track 1: Regulation
Track 1: Regulation
Mar 1510:50
Conference pass

Development of Selected Tumor Infiltrating Lymphocyte Therapies for Solid Tumors

Track 2: Gene modified cell therapy
Stewart Abbot, CSO, Turnestonebio
Track 2: Gene Modified Cell Therapy
Mar 1510:50
Conference pass

Strategies for dynamic expansion of stem cell mimicking physiological microenvironment

Track 3: Cell therapy
Track 3
Mar 1510:50
Conference pass

CRISPR/Cas9 Gene Editing Therapies for Cystic Fibrosis

Track 4: Gene Therapy
Stephen Hart, Professor Of Molecular Genetics, Institute of Child Health - U.C.L.
Track 4
Mar 1510:50
Conference pass

Automating autologous and allogeneic cell therapy manufacturing

Track 5: Cell therapy manufacture
Track 5
Mar 1510:50
Conference pass

How to tackle gene therapy production bottleneck through AAV flexible platforms

Track 6: Viral vector manufacture
Hanna Lesch, CTO, Exothera SA
Mar 1510:50
Conference pass

Treatment of Osteoarthritis with Mesenchymal Stromal Cells – A Whole Patient Approach

Track 8: Innovation Showcase
Jo Miller, Director, Cell Therapy Sciences
Mar 1511:10
Conference pass

EMD-101, an autologous, allele-specific gene-edited hematopoietic stem cell therapy, for treating ELANE related severe congenital neutropenia

Track 2: Gene modified cell therapy
Track 2: Gene Modified Cell Therapy
Mar 1511:10
Conference pass

Generation of stem cell derived functional thymic cells for research and cell therapy

Track 3: Cell therapy
Track 3
Mar 1511:10
Conference pass

Strategy to Accelerate Research in Rare Disease

Track 4: Gene Therapy
Katherine Forsey, Chief Research Officer (based in the UK), Charcot Marie Tooth Association
Track 4
Mar 1511:10
Conference pass

Setting the right path – Early considerations for optimizing value and risk in CMC

Track 5: Cell therapy manufacture
Mar 1511:10
Conference pass

Development of a perfusion process for continuous lentivirus production using stable suspension producer cell lines

Track 6: Viral vector manufacture
Mar 1511:10
Conference pass

Towards the optimal ‘Package’ therapy

Track 7: Clinical Development and Trials
Mar 1511:10
Conference pass

Tackling gene therapy commercialization challenges through intensified and continuous manufacturing

Track 8: Innovation Showcase
Martina Sebastian, Business Development, Univercells Technologies
Mar 1511:10
Conference pass

Regenerative potential of oral mucosa - new possibilities in the treatment of periodontal diseases

Track 9: Start-up theatre
Zuzanna Stern, CEO, Cellivia
Marta Dyszkiewicz-Konwinska, Scientific Advisor, Cellivia
Track 9: Start-up Theatre
Mar 1511:30
Conference pass

Panel: Biotech financing: where are we going in 2023?

Track 1: Commercialisation and business development
Sven Kili, Chief Executive Officer, Antion Biosciences
Track 1: Commercialisation and business development
Mar 1511:30
Conference pass

Panel: Measurable residual disease and novel transplant techniques to optimize outcomes in AML

Track 2: Gene modified cell therapy
Stefan Nierkens, Principal Investigator Boelens/Nierkens Research Group & Head U-DAIR, UMC Utrecht
Andromachi Scaradavou, BMT Attending, Memorial Sloan Kettering cancer center
Track 2: Gene modified cell therapy
Mar 1511:30
Conference pass

Regenerative cardiac cell therapy: an opportunity for curing heart failure – focus on safety

Track 3: Cell therapy
Track 3
Mar 1511:30
Conference pass

Panel: What challenges and opportunities are facing companies and other organisations as they introduce gene therapies to the UK market

Track 4: Gene Therapy
David Edward Rose, Business Development And Sales Associate, Rare Revolution
Nina Pinwill, Head of Commercial Operations, NHS England
John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency
Track 4
Mar 1511:30
Conference pass
Mar 1511:30
Conference pass

Viral Gene Therapy – How Can the Industry Drive Down the Cost of Goods to Better Serve the Patients?

Track 6: Viral vector manufacture
Mar 1511:30
Conference pass

Lomecel-B: an MSC therapy with potential for treatment of Hypoplastic Left Heart Syndrome, Aging-related Frailty and Alzheimer’s Disease

Track 7: Clinical Development and Trials
Mar 1511:30
Conference pass

RNA Therapeutics

Track 8: Innovation Showcase
Sarfaraz Niazi, Adjunct Professor, University of Illinois
Mar 1511:50
Conference pass

Panel: Centring the lived experience at the heart of policy decisions

Track 1: Regulation
Anna Dickinson, Senior Researcher, Science and Technology, Onward
David Edward Rose, Business Development And Sales Associate, Rare Revolution
Daniel Lewi, Co-founder & Chief Executive Officer, The Cure & Action for Tay-Sachs (CATS) Foundation
Track 1: Commercialisation and business devlopment
Mar 1511:50
Conference pass

Autologous cells for muscle regeneration: a translational clinical trial perspective

Track 3: Cell therapy
Deana Mohr, Chief Executive Officer, MUVON Therapeutics
Track 3
Mar 1511:50
Conference pass

Engineering neurogenesis via lineage reprogramming

Track 8: Innovation Showcase
Mar 1511:50
Conference pass

Challenge accepted! Moving toward end-to-end human phenotypic drug discovery

Track 9: Start-up theatre
Track 9: Start-up Theatre
Mar 1512:10
Conference pass

Next Generation Immunotherapies for Cancer and Autoimmune Diseases

Track 2: Gene modified cell therapy
Mar 1512:10
Conference pass

Purification technologies to advance next-generation iPSC-derived therapies into the clinical stage

Track 3: Cell therapy
Mar 1512:10
Conference pass

Leveraging successful platforms for delivering the promise of gene therapy

Track 4: Gene Therapy
Adrien Lemoine, Co-Founder & CEO, Bloomsbury Genetic Therapies
Mar 1512:10
Conference pass

Skip the cleanroom queue: Off-Site modular construction

Track 8: Innovation Showcase
Mar 1512:10
Conference pass

Skip the cleanroom queue: Off-Site modular construction

Track 8: Innovation Showcase
Mar 1513:29
Conference pass

Chair: Snehal Naik, Head of Regulatory Policy; Strategy Leader (Ocular), Spark Therapeutics

Track 1: Regulation
Track 1: Regulation
Mar 1513:29
Conference pass

Chair: Roy Baynes, Senior Vice President, CMO, Eikon Therapeutics

Track 2: Immuno-oncology
Roy Baynes, Senior Vice President Clinical Research, Merck Research Laboratories
Track 2: Immuno-oncology
Mar 1513:29
Conference pass

Chair: Sakis Mantalaris, Professor, Trinity College Dublin

Track 5: Cell therapy manufacture
Track 5
Mar 1513:30
Conference pass

Combination therapy: variations on synergy as a four-letter word

Track 2: Immuno-oncology
Emmett Schmidt, Vice President, Clinical Oncology, Merck Research Laboratories
Track 2: Immuno-oncology
Mar 1513:30
Conference pass
Mar 1513:30
Conference pass

The next level of CRISPR safety: tackling Cas9 immunogenicity

Track 4: Gene Therapy
Track 4
Mar 1513:30
Conference pass

Fully automated platform for organoid production and tissue manufacture

Track 5: Cell therapy manufacture
Track 5
Mar 1513:30
Conference pass

Xenotransplantation – From Bench to Patient

Track 8: Innovation Showcase
Mar 1513:50
Conference pass

Targeting cancer with a new comprehensive stem cell-based immunotherapy, IPVAC

Track 2: Immuno-oncology
Mar 1513:50
Conference pass

Multi-omic profiling of iPSC differentiation to cardiomyocytes identifies critical quality attributes that predict batch outcomes

Track 3: Cell therapy
Track 3
Mar 1513:50
Conference pass

Clinical updates: Leveraging Moderna’s mRNA platform to advance medicines for rare disease patients

Track 4: Gene Therapy
Paolo Martini, CSO Rare Diseases, Hematology and Rare Alliances,, Moderna Therapeutics
Track 4
Mar 1513:50
Conference pass

Bringing novel advanced therapies to patients from a public University Hospital setting

Track 5: Cell therapy manufacture
Mar 1513:50
Conference pass

A novel spiral vane (Bach) impeller for cell and gene therapy manufacturing

Track 8: Innovation Showcase
Steve Oh, Stem Cell Bioprocessing Director And Institute Professor, A-star
Mar 1513:50
Conference pass

Using gene therapy to treat cancer with man-made peptide

Track 9: Start-up theatre
Scott Robinson, CSO, MicroQuin
Track 9: Start-up Theatre
Mar 1514:10
Conference pass

RNA activation in cancer and Rare Genetic Diseases

Track 2: Immuno-oncology
Nagy Habib, Chief Medical Officer, Head of R&D, MiNA Therapeutics Ltd
Mar 1514:10
Conference pass

TBC

Track 3: Cell therapy
Aisha Khan, Executive Director Of Lab Operations At The Interdisciplinary Stem Cell Institute, Miller School of Medicine University of Miami
Track 3
Mar 1514:10
Conference pass

The transformative potential of HSC gene therapy as a genetic medicine

Track 4: Gene Therapy
Track 4
Mar 1514:10
Conference pass

Enabling rapid cell therapy accessibility for patients through simplified, standardized, and consistent manufacturing

Track 5: Cell therapy manufacture
Mar 1514:10
Conference pass

Autologous Cell Therapy – The Journey from Tech Transfer to Clinical Manufacturing

Track 8: Innovation Showcase
Mar 1514:10
Conference pass

Just Silence Cancer!

Track 9: Start-up theatre
Merle Fuchs, CEO, PRAMOMOLECULAR GmbH
Track 9: Start-up Theatre
Mar 1514:30
Conference pass

Early detection and screening for genetic diseases and genetic risk factors

Track 1: Regulation
Track 1: Regulation
Mar 1514:30
Conference pass
Mar 1514:30
Conference pass

State and federal policy in rare disease

Track 4: Gene Therapy
Kimberly Haugstad, Chief Executive Officer, Upequity Corporation
Tara Britt, Associate Chairman, NC Rare Disease Innovations Institute
Track 4
Mar 1514:30
Conference pass

Development of liver tissue implants to treat critically failing liver function in humans

Track 8: Innovation Showcase
Mar 1514:30
Conference pass

Developing regenerative therapies for hearing loss

Track 9: Start-up theatre
Terri Gaskell, CTO, Rinri Therapeutics
Track 9: Start-up Theatre
Mar 1515:20
Conference pass

RNA CAR T cell Therapy for Autoimmune Disease

Track 3: Cell therapy
Andy Stewart, Senior Director of Research, CARTESIAN THERAPEUTICS
Track 3
Mar 1515:20
Conference pass

Harnessing the Power of Known and Novel Capsids to Deliver Gene Therapy to the Heart

Track 4: Gene Therapy
Kathy Ivey, Vice President of Gene Therapy Research, Tenaya Therapeutics
Mar 1515:20
Conference pass

ReStart CNS Regenerating Cells

Track 8: Innovation Showcase
Chris Ahuja, Chief Executive Officer, Inteligex
Mar 1515:20
Conference pass

Oncolytic viruses - a revolutionary approach in immune oncology

Track 9: Start-up theatre
Track 9: Start-up Theatre
Mar 1515:40
Conference pass

iPSC-derived cell therapy to bioengineer de novo hair follicles for the treatment of Alopecia and hair loss

Track 3: Cell therapy
Track 3
Mar 1515:40
Conference pass

Engineering advanced gene therapy platforms

Track 4: Gene Therapy
Track 4
Mar 1516:00
Conference pass

Streamlining Clinical Success: Bioprocessing for Multinational Cell Therapy Trials

Track 3: Cell therapy
Mar 1516:00
Conference pass

Mesenchymal stem cell line-derived extracellular vesicles: Consistent therapeutics for use in musculoskeletal disease

Track 9: Start-up theatre
Track 9: Start-up Theatre
Mar 1516:20
Conference pass

Cord Blood banking in Europe – challenges and opportunities

Track 8: Innovation Showcase
Tomasz Baran, Executive VP, PBKM/FamiCord Group
Mar 1516:40
Conference pass

Cord Blood and Cord Tissue Therapies for Children

Track 8: Innovation Showcase
Joanne Kurtzberg, Professor Of Pediatrics And Pathology; Director, Marcus Center For Cellular Cures,, Duke University Medical Center
Mar 1517:00
Conference pass

Experimental approaches to improve umbilical cord blood transplant outcomes

Track 8: Innovation Showcase
Mar 1517:20
Conference pass

Use of Cord Blood as Starting Material for Cell Therapy

Track 8: Innovation Showcase
Marcie Finney, Executive Director, Cleveland Cord Blood Center
Mar 1517:40
Conference pass

Allogeneic UC-MSC drug product for treatment of type 1 diabetes

Track 8: Innovation Showcase
last published: 07/Feb/23 14:55 GMT


Get in touch with Advanced Therapies Congress

 

To speak


Ila Dickinson
Ila.Dickinson@terrapinn.com
+44 208 164 3086

 

 

To sponsor or exhibit


Ashlea Foster
ashlea.foster@terrapinn.com
+44 208 164 3032